Skip to main content

View full-text article in PMC

. 2017 Mar 16;8(3):e2678. doi: 10.1038/cddis.2017.101

Table 1. Selectivity of DGBP and zoledronate for malignant versus primary cells.

	IC₅₀ (μM) (95% CI)			*Selectivity versusPBMC*
	PBMC	Molt-4	Jurkat	Molt-4	Jurkat
DGBP	1200 (480–3000)	15 (4.7–48)	30 (14–64)	80	40
Zoledronate	63 (32–120)	52 (37–74)	81 (46–140)	1.2	0.78
Fold difference	0.053	3.5	2.7

Abbreviation: DGBP, digeranyl bisphosphonate